Key result
Psychotropic polypharmacy occurs in ~86% of depression patients, linked to middle age and prior episodes.
Why the study?
While psychotropic polypharmacy can be clinically justified, multiple drug use can be problematic, prompting an analysis of its incidence and associated factors in patients with depressive disorders.
What is the incidence of psychotropic polypharmacy and its associated factors in adult patients with depressive disorders receiving antidepressant treatment?
Cohort (n=39,800)
Yes
What is the incidence of psychotropic polypharmacy and its associated factors in adult patients with depressive disorders receiving antidepressant treatment?
Psychotropic polypharmacy is highly prevalent (86.28%) among antidepressant-treated patients with depressive disorders, particularly in those with previous episodes and multiple comorbidities.
Answers are grounded in this paper and cite their sources.
Clinicians should scrutinize psychotropic regimens in depression and anxiety; leaves open net benefit and requires RCTs to inform prescribing.
Introduction Psychotropic polypharmacy typically refers to the prescription of more than one psychotropic medication to a patient. While polypharmacy can sometimes be clinically justified, it is widely recognized that multiple drug use and exposure can be problematic. The aim of this article is to analyze polypharmacy experienced by patients with depressive disorders, estimating its incidence during the first year after diagnosis and exploring the sociodemographic, clinical, and health‐related lifestyle factors related to psychotropic polypharmacy. Methods A retrospective population‐based cohort study was conducted among adults (aged 18 and over) within the Canary Islands Health Service. The study analyzed routine health record data from patients diagnosed with depressive disorders who received antidepressant treatment between 2013 and 2022. Psychotropic polypharmacy refers to the concurrent use of two or more psychotropic medications by the same patient. To explore the relationship with sociodemographic, clinical, and lifestyle characteristics, multivariate logistic regression analyses were conducted. Results The study included a total of 39,800 participants, with a polypharmacy incidence of 86.28%. Most patients (48.10%) received three or more medications ( N = 19,145). Factors associated with polypharmacy included the 45–64 age group (OR: 1.21), previous depressive episodes (OR: 1.15), number of comorbidities (OR: 1.11), and male gender (OR: 0.83). Conclusion The results highlight the complexity of psychotropic polypharmacy, especially in patients with previous episodes and comorbidities. While the use of multiple medications may be necessary, it is critical to periodically review treatments to ensure their safety, especially in vulnerable populations. New prescription trends suggest a shift toward more rational approaches, although further research is required to support clinical guidelines.
No takes yet. Share an insight, caveat, or question.
Infante-Ventura et al. (2026) conducted a cohort in Depressive disorders (n=39,800). Psychotropic polypharmacy was evaluated on Incidence of psychotropic polypharmacy during the first year after diagnosis. In patients with depressive disorders, the incidence of psychotropic polypharmacy was 86.28%, with factors such as age 45-64 (OR 1.21) and previous depressive episodes (OR 1.15) increasing risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: